Curbside Consult: Optimizing IgAN Management

ReachMD Healthcare Image
Media formats available:
Details
Presenters
Related
Comments
  • Overview

    Using a case-based vignette, faculty members will review emerging clinical trial data in IgAN and provide expert analysis regarding the value of lowering proteinuria. Learn how novel mechanisms, innovative treatments, and emerging data are leading to successful outcomes in patients with IgAN.

    Post publication of this educational activity, the European Commission has approved sparsentan for the treatment of patients with IgA Nephropathy (IgAN) on April 24, 2024. Sparsentan is the first and only non-immunosuppressive therapy approved for adults with primary IgAN with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g).

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Khalil El Karoui, MD
    Département de Néphrologie
    AP-HP. Sorbonne Université
    CoRaKiD: UMRS 1155 - Common and Rare Kidney Diseases
    Hôpital Tenon
    Paris, France

    Dr. El Karoui has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: 
    Consulting Fees: CSL Vifor

    Faculty:
    Federico Alberici, MD, PhD
    Associate Professor
    Director of the Nephrology Unit
    Director of the School of Specialization in Nephrology
    University of Brescia - ASST Spedali Civili
    Brescia, Italy

    No relevant relationships reported

    Content Directors, Planners, Peer Reviewers, and Relevant Staff:

    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Howard J. Green, MS, MBA, has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Katie Sheridan, PhD, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Demonstrate the application of clinical reasoning to achieve a timelier and more accurate diagnosis for patients with immunoglobulin A nephropathy (IgAN)
    • Evaluate the existing therapeutic gaps in addressing the unmet needs of patients with IgAN
    • Apply recent clinical trial findings into real-world patient scenarios to optimize outcomes in patients with IgAN
  • Target Audience

    This activity is designed to meet the educational needs of nephrologists and rheumatologists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from CSL Vifor.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

NEW FEATURES:

Register

We're glad to see you're enjoying Global Kidney Academy…
but how about a more personalized experience?

Register for free